Implementation of guidelines for implantable cardioverter-defibrillator therapy in clinical practice: Which patients do benefit?

Netherlands Heart Journal

Volumn 21, Issue 6, 2013, Pages 274-283

  Wijers, S C ^a   van der Kolk, B Y M ^a   Tuinenburg, A E ^a   Doevendans, P A F ^a   Vos, M A ^a   Meine, M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Implantable cardioverter defibrillator; Mortality; Primary prevention; Secondary prevention; Ventricular arrhythmia

Indexed keywords

ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; ARTICLE; CARDIOGENIC SHOCK; CLINICAL PRACTICE; ECHOGRAPHY; FEMALE; HAZARD RATIO; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PACING; HEART VENTRICLE TACHYCARDIA; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; IMPLANTATION; ISCHEMIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONISCHEMIC CARDIOMYOPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; SUPRAVENTRICULAR TACHYCARDIA; TACHYCARDIA;

EID: 84878243575     PISSN: 15685888     EISSN: 18766250     Source Type: Journal    
DOI: 10.1007/s12471-013-0407-x     Document Type: Article

References (51)

1. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter automatic defibrillator implantation trial investigators. N Engl J Med. 1996;335(26):1933-40.
2. Antiarrhythmics versus Implantable Defibrillators (AVID) investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997 Nov 27;337(22):1576-83
3. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225-37.
4. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter unsustained tachycardia trial investigators. N Engl J Med. 1999;341(25):1882-90.
5. Connolly SJ, Gent M, Roberts RS, et al. Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101(11):1297-302.
6. Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350(21):2151-8.
7. Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102(7):748-54.
8. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877-83.
9. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm Abnormalities: a report of the American college of cardiology/ American heart association task force on practice guidelines (writing committee to revise the ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices) developed in collaboration with theAmerican association for thoracic surgery and society of thoracic surgeons. J Am Coll Cardiol. 2008;51(21):e1-e62.
10. van Erven L, van Dessel PFHM, Simmers TA, et al. Guidelines ICD implantation 2005-an update. The Netherlands Society of Cardiology (Nederlandse Vereniging voor Cardiologie), version April 2006.
11. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American college of cardiology/american heart association task force and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European heart rhythm association and the heart rhythm society. Europace. 2006;8(9):746-837.
12. Mark DB, Nelson CL, Anstrom KJ, et al. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation. 2006;114(2):135-42.
13. Zwanziger J, Hall WJ, Dick AW, et al. The cost effectiveness of implantable cardioverter-defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol. 2006;47(11):2310-8.
14. Cowie MR, Marshall D, Drummond M, et al. Lifetime costeffectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population. Europace. 2009;11(6):716-26.
15. Smith T, Jordaens L, Theuns DA, et al. The cost-effectiveness of primary prophylactic implantable defibrillator therapy in patients with ischaemic or non-ischaemic heart disease: a European analysis. Eur Heart J. 2013;34(3):211-9.
16. Bracke FA, Dekker LR, van der Voort PH, et al. Primary prevention with the ICD in clinical practice: not as straightforward as the guidelines suggest? Neth Heart J. 2009;17(3):107-10.
17. van Welsenes GH, Borleffs CJ, van Rees JB, et al. Improvements in 25 Years of implantable cardioverter defibrillator therapy. Neth Heart J. 2011;19(1):24-30.
18. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American college of cardiology/American heart association task force and the European society of cardiology committee for practice Guidelines (writing committee to develop guidelines formanagement of patients with ventricular arrhythmias and the prevention of sudden cardiac death). J Am Coll Cardiol. 2006;48(5):e247-346.
19. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med. 1999;130(6):461-70.
20. Vaughan Williams EM. Classification of antidysrhythmic drugs. Pharmacol Ther B. 1975;1(1):115-38.
21. Follath F. Nonischemic heart failure: epidemiology, pathophysiology, and progression of disease. J Cardiovasc Pharmacol. 1999;33 Suppl 3:S31-5.
22. Borleffs CJ, Wilde AA, Cramer MJ, et al. Clinical implementation of guidelines for cardioverter defibrillator implantation: lost in translation? Neth Heart J. 2007;15(4):129-32.
23. Al-Khatib SM, Sanders GD, CarlsonM, et al. Preventing tomorrow's sudden cardiac death today: dissemination of effective therapies for sudden cardiac death prevention. Am Hear J. 2008;156(4):613-22.
24. van Welsenes GH, van Rees JB, Borleffs CJ, et al. Long-term follow-up of primary and secondary prevention implantable cardioverter defibrillator patients. Europace. 2011;13(3):389-94.
25. Smith T, van Dessel PF, Theuns DA, et al. Health care utilisation after defibrillator implantation for primary prevention according to the guidelines in 2 Dutch academic medical centres. Neth Heart J. 2011;19(10):405-11.
26. Moss AJ, Greenberg H, Case RB, et al. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation. 2004;110(25):3760-5.
27. Bansch D, Antz M, Boczor S, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation. 2002;105(12):1453-8.
28. Strickberger SA, Hummel JD, Bartlett TG, et al. Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia-AMIOVIRT. J Am Coll Cardiol. 2003;41(10):1707-12.
29. Desai AS, Fang JC, Maisel WH, et al. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. Jama. 2004;292(23):2874-9.
30. Wilson D, Shi B, Harding S, et al. Implantable cardioverterdefibrillators: a long-term view. Intern Med J. 2012;42(5):554-61 [Research Support, Non-U.S. Gov't].
31. Goldenberg I, Gillespie J, Moss AJ, et al. Long-term benefit of primary prevention with an implantable cardioverter-defibrillator: an extended 8-year follow-up study of the multicenter automatic defibrillator implantation trial II. Circulation. 2010;122(13):1265-71.
32. Santangeli P, Pelargonio G, Dello Russo A, et al. Gender differences in clinical outcome and primary prevention defibrillator benefit in patients with severe left ventricular dysfunction: a systematic review and meta-analysis. Hear Rhythm. 2010;7(7):876-82.
33. Haigney MC, Zareba W, Nasir JM, et al. Gender differences and risk of ventricular tachycardia or ventricular fibrillation. Hear Rhythm. 2009;6(2):180-6.
34. Ghanbari H, Dalloul G, Hasan R, et al. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials. Arch Intern Med. 2009;169(16):1500-6.
35. MacFadden DR, Crystal E, Krahn AD, et al. Sex differences in implantable cardioverter-defibrillator outcomes: findings from a prospective defibrillator database. Ann Intern Med. 2012;156(3):195-203.
36. Heller SS, Ormont MA, Lidagoster L, et al. Psychosocial outcome after ICD implantation: a current perspective. Pacing Clin Electrophysiol. 1998;21(6):1207-15.
37. Schron EB, Exner DV, Yao Q, et al. Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation. 2002;105(5):589-94.
38. van Rees JB, Borleffs CJ, de Bie MK, et al. Inappropriate implantable cardioverter-defibrillator shocks: incidence, predictors, and impact on mortality. J Am Coll Cardiol. 2011;57(5):556-62.
39. Ellenbogen KA, Levine JH, Berger RD, et al. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy? Circulation. 2006;113(6):776-82.
40. Daubert JP, Zareba W, Cannom DS, et al. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol. 2008;51(14):1357-65.
41. Alter P, Waldhans S, Plachta E, et al. Complications of implantable cardioverter defibrillator therapy in 440 consecutive patients. Pacing Clin Electrophysiol. 2005;28(9):926-32.
42. Borleffs CJ, van Welsenes GH, van Bommel RJ, et al. Mortality risk score in primary prevention implantable cardioverter defibrillator recipients with non-ischaemic or ischaemic heart disease. Eur Heart J. 2010;31(6):712-8.
43. van Rees JB, Borleffs CJ, vanWelsenes GH, et al. Clinical prediction model for death prior to appropriate therapy in primary prevention implantable cardioverter defibrillator patients with ischaemic heart disease: the FADES risk score. Heart. 2012;98(11):872-7.
44. Multicenter Postinfarction Research Group. Risk stratification and survival after myocardial infarction. N Engl J Med. 1983 Aug 11;309(6):331-6.
45. Wilde AA, Simmers TA. Primary prevention with ICDs, are we on the right track? Neth Heart J. 2009;17(3):92-4.
46. de Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI, et al. Out-of-hospital cardiac arrest in the 1990's: a population-based study in the Maastricht area on incidence, characteristics and survival. J Am Coll Cardiol. 1997;30(6):1500-5.
47. Jackson CE, Myles RC, Tsorlalis IK, et al. Profile ofmicrovolt T-wave alternans testing in 1003 patients hospitalized with heart failure. Eur J Heart Fail. 2012;14(4):377-86 [Research Support, Non-U.S. Gov't].
48. Kraaier K, McCracken T, van der Palen J, et al. Is T-wave alternans testing feasible in candidates for prophylactic implantable defibrillators? Neth Heart J. 2011;19(1):6-9.
49. Amit G, Rosenbaum DS, Super DM, et al. Microvolt T-wave alternans and electrophysiologic testing predict distinct arrhythmia substrates: implications for identifying patients at risk for sudden cardiac death. Hear Rhythm. 2010;7(6):763-8.
50. Seegers J, Vos MA, Flevari P, et al. Rationale, objectives, and design of the EUTrigTreat clinical study: a prospective observational study for arrhythmia risk stratification and assessment of interrelationships among repolarization markers and genotype. Europace. 2012;14(3):416-22.
51. Varkevisser R, Wijers SC, van der Heyden MA, et al. Beat-to-beat variability of repolarization as a new biomarker for proarrhythmia in vivo. Hear Rhythm. 2012;9(10):1718-26.